Tenof EM
Molecular Salt: Tenofovir Disoproxil-Emtricitabine
Tenof EM (Tenofovir disoproxil fumarate + Emtricitabine) is a two-drug agent indicated to manage HIV-1 and HIV-1 pre-exposure prophylaxis (PrEP). Both tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) are employed in combination along with other antiretroviral agents.
Before starting Tenof EM (Tenofovir disoproxil fumarate + Emtricitabine) regimen, it is important to make sure that the patients are tested for chronic kidney disease, HIV-1 PrEP or Hepatitis B viral co-infection. Plus, these patients must have a bodyweight of greater than or equal to 35 kgs
Recommended dosage regimen of Tenof EM (Tenofovir disoproxil fumarate + Emtricitabine)
Patient population | Dosage regimen (Once daily) | Bodyweight | Mode of administration |
Adults | 1 tablet of Tenof EM (Tenofovir disoproxil fumarate + Emtricitabine) | ≥35 kgs | Orally with or without food |
Children | |||
HIV-1 PrEP adults | 1 tablet of Tenof EM (Tenofovir disoproxil fumarate + Emtricitabine) and other contraceptive methods | ||
Kidney failure patients (Creatinine clearance: 30-49 mL/min) | 1 tablet of Tenof EM (Tenofovir disoproxil fumarate + Emtricitabine) every 48 hours |
Other activities of (Tenofovir disoproxil fumarate + Emtricitabine):
Once the drug is swallowed, both molecules carry out their activities in unique ways. Tenofovir takes around 40 minutes to 1 hour whereas, emtricitabine requires 1-2 hours for absorbing in our system. However, when it comes to excretion, 17 hours are enough for tenofovir to expel out 50% of the drug i.e. 7 hours (10 hours) higher than emtricitabine.
Side-effects of Tenof EM (Tenofovir disoproxil fumarate + Emtricitabine):
Patients with HIV-1 infection | Patients who took the drug to reduce the incidence of HIV-1 infection |
Difficulty in sleeping (Insomnia) | Headache |
Rashes on the skin | Pain in the abdomen (stomach area) |
Tiredness (Fatigue) | Loss of weight |
Diarrhea | |
Headache | |
Nausea |
Note: Tenof EM (Tenofovir disoproxil fumarate + Emtricitabine) may show other side-effects too, for additional information please consult your doctor
Severe conditions associated with administration of Tenof EM (Tenofovir disoproxil fumarate + Emtricitabine):
There are certain conditions wherein either discontinuing the treatment or the component or drug itself could lead to severe complications. Under such scenarios, it is crucial to consult your doctor immediately for safety. These include,
- Severe acute complications in the liver with Hepatitis B viral infection
- Acute kidney failure
- Inflammation occurring due to immune reconstitution syndrome
- Reduced bone mineral density (Weakened bones)
- Excessive amount of lactic acid in the blood (lactic acidosis)
- Hepatotoxicity
Warnings for HIV-1 PrEP patients:
- Patients should avoid (Tenofovir disoproxil fumarate + Emtricitabine) unless they are confirmed as HIV-negative
- Use all possible contraceptive methods for preventing the transmission of new HIV-1 infection
- Make sure that your partner isn’t HIV-1 positive nor taking other anti-HIV medications
- Undertake regular HIV-1 testing (3 months or when your doctor suggests)
- Avoid missing any dose of (Tenofovir disoproxil fumarate + Emtricitabine)
Hetero Healthcare
Tablet (300 mg/200 mg)
30 Tablets
Store below 30°C
Product Enquiry
Submit an enquiry for wholesale sourcing, pricing, and cold-chain delivery. Our team responds within 24 hours.
Clinical Advisory & Import Compliance
Disclaimer: Gandhi Medicos is a clinical specialty supplier and exporter. All enquiries are subject to valid licensing verification and import permits standard under target jurisdiction guidelines.
Storage Warning: Biological injectables, biosimilars, and active oncology agents are flagged as temperature-sensitive cargo and are packed strictly inside thermal containers coupled with real-time digital temperature tags.